Cited by 3,207Colorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Open access

Amado, Rafael G., Wolf, Michael, Peeters, Marc, Van Cutsem, Eric, Siena, Salvatore, Freeman, Daniel J., Juan, Todd, Sikorski, Robert, Suggs, Sid, Radinsky, Robert, Patterson, Scott D., Chang, David D.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.7116

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. Patients and Methods: KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status. Results: KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population. Conclusion: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.7116

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citation
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
Newton, C. R., Graham, A., Heptinstall, L., Powell, S. J., Summers, C. W., Kalsheker, N. A., Smith, J. C., & Markham, A. F. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.7.2503 · Cited by 2,483

Show all 38 references

Sorted by citations

Items 101–200 of 1,014

Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)
Dewdney, A., Cunningham, D., Tabernero, J. M., Capdevila, J., Glimelius, B. L. G., Cervantes, A. M. R., Tait, D., Brown, G. M., Wotherspoon, A. C., de Castro, D. G., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6036 · Cited by 388
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
Seymour, M., Brown, S., Middleton, G., Maughan, T., Richman, S. D., Gwyther, S. J., Lowe, C., Seligmann, J., Wadsley, J., Maisey, N. R., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70163-3 · Cited by 392
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
Vaughn, C. P., ZoBell, S. D., Furtado, L. V., Baker, C. L., & Samowitz, W. S. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20854 · Cited by 377
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Adam, M. A., Chang, G. J., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Garrido‐Laguna, I., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0029 · Cited by 433
Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
McConkey, D. J., Choi, W., Marquis, L., Martin, F. M., Williams, M. B., Shah, J. B., Svatek, R. S., Das, A., Adam, L., Kamat, A. M., et al. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9194-7 · Cited by 371
Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality
Aran, V., Victorino, A. P., Thuler, L. C. S., & Ferreira, C. G. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.02.008 · Cited by 364
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.07.010 · Cited by 361
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
Nordlinger, B., Cutsem, E. V., Gruenberger, T., Glimelius, B. L. G., Poston, G. J., Rougier, P. R., Sobrero, A. F., & Ychou, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn735 · Cited by 355
Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action
Zhao, S., & Iyengar, R. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134520 · Cited by 366
Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
Tejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C., & Van Cutsem, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2592 · Cited by 353
Colorectal cancer molecular biology moves into clinical practice
Pritchard, C. C., & Grady, W. M. (2010) · Gut · doi:10.1136/gut.2009.206250 · Cited by 363
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
Personalized medicine in oncology: the future is now
Schilsky, R. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3181 · Cited by 347
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
Martinelli, E., Palma, R. D., Orditura, M., Vita, F. D., & Ciardiello, F. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03992.x · Cited by 348
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
Stein, E. M., Dinardo, C. D., Fathi, A. T., Pollyea, D. A., Stone, R. M., Altman, J. K., Roboz, G. J., Patel, M. R., Collins, R. H., Flinn, I. W., et al. (2018) · Blood · doi:10.1182/blood-2018-08-869008 · Cited by 330
Treatment sequencing in metastatic colorectal cancer
Modest, D. P., Pant, S., & Bianchi, A. S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.019 · Cited by 337
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns
Schuh, A., Becq, J., Humphray, S., Alexa, A., Burns, A., Clifford, R. M., Feller, S. M., Grocock, R., Henderson, S. J., Khrebtukova, I., et al. (2012) · Blood · doi:10.1182/blood-2012-05-433540 · Cited by 321
Portrait of the PI3K/AKT pathway in colorectal cancer
Danielsen, S. A., Eide, P. W., Nesbakken, A., Guren, T. K., Leithe, E., & Lothe, R. A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.008 · Cited by 336
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
Fakih, M. G., Kopetz, S., Kuboki, Y., Kim, T. W., Munster, P. N., Krauss, J. C., Falchook, G. S., Han, S.-W., Heinemann, V., Muro, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00605-7 · Cited by 320
Biomarkers and surrogate end points—the challenge of statistical validation
Buyse, M. E., Sargent, D. J., Grothey, A. F., Matheson, A., & de Gramont, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.43 · Cited by 320
High frequency of BRAF V600E mutations in ameloblastoma
Kurppa, K. J., Catón, J., Morgan, P. R., Ristimaki, A. P., Ruhin, B., Kellokoski, J. K., Elenius, K., & Heikinheimo, K. (2013) · The Journal of Pathology · doi:10.1002/path.4317 · Cited by 311
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
Souglakos, J., Philips, J., Wang, R., Marwah, S., Silver, M. H., Tzardi, M. N., Silver, J., Ogino, S., Hooshmand, S. M., Kwak, E. L., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605164 · Cited by 315
Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
Higgins, M. J., Jelovac, D., Barnathan, E., Blair, B., Slater, S. A., Powers, P., Zorzi, J., Jeter, S. C., Oliver, G. R., Fetting, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2696 · Cited by 311
The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
Parato, K. A., Breitbach, C. J., Boeuf, F. L., Wang, J., Storbeck, C. J., Ilkow, C. S., Diallo, J., Falls, T. J., Burns, J. K., Garcia, V., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.276 · Cited by 305
BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives
Sanz‐García, E., Argilés, G., Élez, E., & Tabernero, J. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx401 · Cited by 308
Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer
Yang, J., Mo, J., Dai, J., Ye, C., Cen, W., Zheng, X., Jiang, L., & Ye, L. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04367-3 · Cited by 300
“Treatment with cetuximab is ineffective in CRC patients with KRAS mutations [6, 7].”
Background
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
Pinyol, R., Montal, R., Bassaganyas, L., Sia, D., Takayama, T., Chau, G.-Y., Mazzaferro, V., Roayaie, S., Lee, H. C., Kokudo, N., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316408 · Cited by 326
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
Prenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B., Lambrechts, D., Van Cutsem, E., & Tejpar, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2961 · Cited by 291
KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
Knijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291
Molecularly targeted cancer therapy: some lessons from the past decade
Huang, M., Shen, A., Ding, J., & Geng, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.004 · Cited by 296
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
Rothwell, D. G., Ayub, M., Cook, N., Thistlethwaite, F. C., Carter, L., Dean, E. J., Smith, N., Villa, S., Dransfield, J., Clipson, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0380-z · Cited by 294
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
van Krieken, J. H., Jung, A., Kirchner, T., Carneiro, F., Seruca, R., Bosman, F. T., Quirke, P., Fléjou, J., Hansen, T. P., Hertogh, G. D., et al. (2008) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-008-0665-y · Cited by 294
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & Bono, J. S. D. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2870 · Cited by 280
Subgroup identification based on differential effect search—A recursive partitioning method for establishing response to treatment in patient subpopulations
Lipkovich, I. A., Dmitrienko, A. A., Denne, J. S., & Enas, G. G. (2011) · Statistics in Medicine · doi:10.1002/sim.4289 · Cited by 275
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K. N., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 301
Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
Vakiani, E., Janakiraman, M., Shen, R., Sinha, R., Zeng, Z., Shia, J., Cercek, A., Kemeny, N. E., D'Angelica, M. I., Viale, A. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2994 · Cited by 288
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF -Mutant Metastatic Colorectal Cancer Patients
Yaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2779 · Cited by 276
Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial
Braun, M. S., Richman, S. D., Quirke, P., Daly, C. L., Adlard, J., Elliott, F., Barrett, J. H., Selby, P. J., Meade, A. M., Stephens, R. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5580 · Cited by 277
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
Brugger, W., Triller, N., Błasińska-Morawiec, M., Curescu, S., Sakalauskas, R., Manikhas, G. M., Mazières, J., Whittom, R., Ward, C., Mayne, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8162 · Cited by 284
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Arena, S., Bellosillo, B., Siravegna, G., Martínez, A., Cañadas, I., Lazzari, L., Ferruz, N., Russo, M., Misale, S., González, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2821 · Cited by 271
Systems Biology Modeling of the Radiation Sensitivity Network: A Biomarker Discovery Platform
Eschrich, S. A., Zhang, H., Zhao, H., Boulware, D. C., Lee, J., Bloom, G. C., & Torres–Roca, J. F. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.05.056 · Cited by 276
KRAS: From undruggable to a druggable Cancer Target
Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102070 · Cited by 271
S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008
Schmiegel, W., Reinacher‐Schick, A., Arnold, D., Graeven, U., Heinemann, V., Porschen, R., Riemann, J. F., Rödel, C. M., Sauer, R., Wieser, M., et al. (2008) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027726 · Cited by 275
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 287
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples
Renfro, L. A., & Sargent, D. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw413 · Cited by 281
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer
Ychou, M., Hohenberger, W., Thézenas, S., Navarro, M., Maurel, J., Bokemeyer, C., Shacham‐Shmueli, E., Rivera, F., Choi, C. K.-K., & Santoro, A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp236 · Cited by 270
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
Verissimo, C. S., Overmeer, R. M., Ponsioen, B., Drost, J., Mertens, S., Verlaan-Klink, I., Gerwen, B. V., van der Ven, M., Wetering, M. V. D., Egan, D. A., et al. (2016) · eLife · doi:10.7554/elife.18489 · Cited by 263
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases
Brudvik, K. W., Jones, R. P., Giuliante, F., Shindoh, J., Passot, G., Chung, M., Song, J., Li, L., Dagenborg, V. J., Fretland, Å. A., et al. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000002319 · Cited by 261
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Sartore-Bianchi, A., Di Nicolantonio, F., Nichelatti, M., Molinari, F., De Dosso, S., Saletti, P., Martini, M., Cipani, T., Marrapese, G., Mazzucchelli, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007287 · Cited by 259
Self-citation
Pharmacogenomics and Individualized Medicine: Translating Science Into Practice
Crews, K. R., Hicks, J. K., Pui, C.-H., Relling, M. V., & Evans, W. E. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.120 · Cited by 255
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K., Marzo, A. M. D., Hammond, M. E. H., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 262
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
Parseghian, C. M., Loree, J. M., Morris, V. K., Liu, X., Clifton, K., Napolitano, S., Henry, J. T., Pereira, A. A. L., Vilar, E., Johnson, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy509 · Cited by 258
Quantitative Cell-Free DNA, KRAS , and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
Spindler, K. G., Pallisgaard, N., Vogelius, I. R., & Jakobsen, A. K. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0564 · Cited by 256
Biomarkers in Colorectal Cancer: Current Research and Future Prospects
Ogunwobi, O. O., Mahmood, F., & Akingboye, A. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155311 · Cited by 255
Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., Garcia-Aguilar, J., & Kim, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012153 · Cited by 244
Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
Peeters, M., Oliner, K. S., Parker, A. N., Siena, S., Cutsem, E. V., Huang, J., Humblet, Y., Laethem, J. V., André, T., Wiezorek, J. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1913 · Cited by 244
Self-citation
The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (Review)
Nguyen, H., & Duong, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8679 · Cited by 244
The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Hurwitz, H. I., Yi, J., Ince, W., Novotny, W. F., & Rosen, O. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0213 · Cited by 239
Precision oncology in metastatic colorectal cancer — from biology to medicine
Nicolantonio, F. D., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J. M., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 244
Self-citation
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
Masi, G., Loupakis, F., Salvatore, L., Fornaro, L., Cremolini, C., Cupini, S., Ciarlo, A., Monte, F. D., Cortesi, E., AMOROSO, D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70175-3 · Cited by 239
PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer
Majewski, I. J., Nuciforo, P. G., Mittempergher, L., Bosma, A. J., Eidtmann, H., Holmes, E. M., Sotiriou, C. P., Fumagalli, D., Jimenez, J., Aura, C. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2158 · Cited by 239
Metastatic Colorectal Cancer: From Improved Survival to Potential Cure
Gallagher, D. J., & Kemeny, N. E. (2010) · Oncology · doi:10.1159/000315730 · Cited by 241
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
Santini, D., Loupakis, F., Vincenzi, B., Floriani, I., Stasi, I., Canestrari, E., Rulli, E., Maltese, P. E., Andreoni, F., Masi, G., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0181 · Cited by 234
Clinical development of targeted and immune based anti-cancer therapies
Seebacher, N. A., Stacy, A. E., Porter, G., & Merlot, A. M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1094-2 · Cited by 241
Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab
Peeters, M., Douillard, J.-Y., Van Cutsem, E., Siena, S., Zhang, K., Williams, R., & Wiezorek, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1492 · Cited by 232
Self-citation
Emerging strategies to target RAS signaling in human cancer therapy
Chen, K., Zhang, Y., Qian, L. M., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 247
KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer
Tie, J., Lipton, L., Desai, J., Gibbs, P., Jorissen, R. N., Christie, M., Drummond, K. J., Thomson, B. N. J., Usatoff, V., Evans, P. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1720 · Cited by 217
Multi‐marker analysis of circulating cell‐free DNA toward personalized medicine for colorectal cancer
Mouliere, F. C., Messaoudi, S. E., Pang, D., Dritschilo, A., & Thierry, A. R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.02.005 · Cited by 234
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Monzon, F. A. (2009) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/s1077-9108(08)79091-1 · Cited by 230
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 241
KRAS mutation testing in metastatic colorectal cancer.
Tan, C., & Du, X. (2012) · PubMed · doi:10.3748/wjg.v18.i37.5171 · Cited by 238
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
Khan, K. H., Cunningham, D., Werner, B., Vlachogiannis, G., Spiteri, I., Heide, T., Fernández-Mateos, J., Vatsiou, A. I., Lampis, A., Darvish-Damavandi, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0891 · Cited by 227
Personalized Medicine and Cancer
Verma, M. (2012) · Journal of Personalized Medicine · doi:10.3390/jpm2010001 · Cited by 234
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients
Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11530-0 · Cited by 215
Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence
Gao, R. W., Teraphongphom, N. T., van den Berg, N. S., Martin, B. A., Oberhelman, N. J., Divi, V., Kaplan, M. J., Hong, S. S., Lu, G., Ertsey, R. D., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0878 · Cited by 218
Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
Peeters, M., Price, T. J., Cervantes, A. M. R., Sobrero, A. F., Ducreux, M. P., Hotko, Y., André, T., Chan, E. W., Lordick, F., Punt, C. J. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt523 · Cited by 218
Self-citation
Mutations of KRAS and BRAF in Primary and Matched Metastatic Sites of Colorectal Cancer
Artale, S., Sartore-Bianchi, A., Veronese, S. M., Gambi, V., Sarnataro, C. S., Gambacorta, M., Lauricella, C., & Siena, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7286 · Cited by 192
Self-citation
Cancer pharmacogenomics: strategies and challenges
Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J., & Ratain, M. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3352 · Cited by 221
Recent Therapeutic Advances in the Treatment of Colorectal Cancer
Ciombor, K. K., Wu, C. S.-Y., & Goldberg, R. M. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-051513-102539 · Cited by 223
KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A., & Eckhardt, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8168 · Cited by 217
Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases
Brudvik, K. W., Kopetz, S., Li, L., Conrad, C. H., Aloia, T. A., & Vauthey, J.-N. (2015) · British journal of surgery · doi:10.1002/bjs.9870 · Cited by 214
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Santini, D., Vincenzi, B., Addeo, R., Garufi, C., Masi, G., Scartozzi, M., Mancuso, A. P., Frezza, A. M., Venditti, O., Imperatori, M., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr623 · Cited by 212
Validation of a Radiosensitivity Molecular Signature in Breast Cancer
Eschrich, S. A., Fulp, W. J., Yudi Pawitan, Y., Foekens, J. A., Smid, M., Martens, J. W. M., Echevarria, M., Kamath, V. P., Lee, J., Harris, E. E. R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0891 · Cited by 215
Predictive and prognostic molecular markers for cancer medicine
Mehta, S. Y., Shelling, A. N., Muthukaruppan, A., Lasham, A., Blenkiron, C., Laking, G. R., & Print, C. G. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009360519 · Cited by 213
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
Tol, J., Dijkstra, J. R., Klomp, M., Teerenstra, S., Dommerholt, M., Vink-Börger, M. E., van Cleef, P. H. J., van Krieken, J. H., Punt, C. J. A., & Nagtegaal, I. D. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.036 · Cited by 215
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
Price, T. J., Hardingham, J. E., Lee, C. K., Weickhardt, A. J., Townsend, A. R., Wrin, J., Chua, A., Shivasami, A., Cummins, M. M., Murone, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5520 · Cited by 210
Drug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 222
BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies.
Clarke, C. N., & Kopetz, S. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.077 · Cited by 211
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
O'Byrne, K. J., Gatzemeier, U., Bondarenko, I., Barrios, C. H., Eschbach, C., Martens, U. M., Hotko, Y., Kortsik, C., Paz-Ares, L. G., Pereira, J. R., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70189-9 · Cited by 209
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
Jankú, F., Lee, J. J., Tsimberidou, A. M., Hong, D. S., Naing, A., Falchook, G. S., Fu, S., Luthra, R., Garrido‐Laguna, I., & Kurzrock, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022769 · Cited by 207
A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Angevin, E., Tabernero, J. M., Élez, E., Cohen, S. J., Bahleda, R., Laethem, J. V., Ottensmeier, C. H. H., Lopez-Martin, J. A., Clive, S., Joly, F., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2200 · Cited by 205
Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
Heinemann, V., Stintzing, S., Kirchner, T., Boeck, S. H., & Jung, A. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.005 · Cited by 209
Clinical Trial Designs for Evaluating the Medical Utility of Prognostic and Predictive Biomarkers in Oncology
Simon, R. (2010) · Personalized Medicine · doi:10.2217/pme.09.49 · Cited by 206
Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Cutsem, E. V., & Oliveira, J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp130 · Cited by 202
Mitogen‐activated protein kinase activity drives cell trajectories in colorectal cancer
Uhlitz, F., Bischoff, P., Peidli, S., Sieber, A., Obermayer, B., Blanc, E., Trinks, A., Lüthen, M., Ruchiy, Y., Sell, T., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114123 · Cited by 195

Authors: Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D., & Chang, D. D.
Affiliations: Ghent University Hospital (BE)
Amgen (United States) (US)
From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca’ Granda, Milan, Italy
ORCID: Amado, Rafael G.
Peeters, Marc
Siena, Salvatore
Patterson, Scott D.
Chang, David D.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-04-01
Volume: 26
Issue: 10
Pages: 1626-1634
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.7116
OpenAlex: W2106789440
Cited by: 3,207
References: 38
Citations by year: 2026: 32 · 2025: 48 · 2024: 59 · 2023: 77 · 2022: 112 · 2021: 123 · 2020: 106 · 2019: 135 · 2018: 131 · 2017: 163 · 2016: 181 · 2015: 253 · 2014: 280 · 2013: 254 · 2012: 288
FWCI: 169.59
Type: journal article
Language: en
Update notices: new_edition (2023-06-14)
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Funders: Amgen
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: panitumumab, KRAS wild-type, KRAS mutation, metastatic colorectal cancer, anti-EGFR therapy, epidermal growth factor receptor, biomarker selection, progression-free survival, best supportive care, treatment toxicity, patient selection
MeSH terms: Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Polymerase Chain Reaction, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, Drug Resistance, Neoplasm, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks